Landscape Capital Management L.L.C. Has $2.16 Million Stock Position in Medtronic PLC $MDT

Landscape Capital Management L.L.C. boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 311.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 22,526 shares of the medical technology company’s stock after buying an additional 17,056 shares during the period. Landscape Capital Management L.L.C.’s holdings in Medtronic were worth $2,164,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Lodestone Wealth Management LLC acquired a new position in Medtronic during the fourth quarter valued at $27,000. Anfield Capital Management LLC raised its position in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the period. Board of the Pension Protection Fund acquired a new position in Medtronic during the fourth quarter valued at $29,000. GoalVest Advisory LLC acquired a new position in Medtronic during the fourth quarter valued at $29,000. Finally, Acumen Wealth Advisors LLC acquired a new position in Medtronic during the fourth quarter valued at $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Medtronic Trading Up 0.2%

Medtronic stock opened at $80.37 on Tuesday. The business has a 50 day moving average price of $80.73 and a two-hundred day moving average price of $91.12. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market cap of $103.19 billion, a price-to-earnings ratio of 21.55, a price-to-earnings-growth ratio of 2.30 and a beta of 0.58. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the prior year, the firm posted $1.62 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date of this dividend is Friday, June 26th. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is currently 76.14%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MDT shares. Stifel Nicolaus set a $80.00 price target on Medtronic in a research report on Wednesday, June 3rd. UBS Group decreased their target price on Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Mizuho decreased their target price on Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday, June 3rd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $88.00 price target on shares of Medtronic in a report on Thursday, June 4th. Finally, Piper Sandler cut their price target on Medtronic from $91.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Seventeen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).